PW Medtech discloses 700,000-share repurchase on 10 September; cumulative buybacks rise to 4.41 million shares

Bulletin Express

Sep 10

PW Medtech Group Limited submitted a Next Day Disclosure Return to the Hong Kong Stock Exchange on 10 September 2026 detailing its latest share repurchase activity and current share capital position.

Key points

• Latest on-market buyback: On 10 September 2026 the company repurchased 700,000 ordinary shares on the Exchange at prices ranging from HKD 0.965 to HKD 0.98, for a total consideration of HKD 0.68 million. • Ongoing cancellation process: Including this transaction, PW Medtech now holds 4.41 million shares pending cancellation—equivalent to 0.31% of the company’s issued share capital as at the 26 June 2026 mandate date. • Repurchase mandate headroom: The board is authorised to buy back up to 144.29 million shares; purchases to date utilise approximately 3.06% of the approved limit. • Share capital unchanged: Issued shares stood at 1.43 billion as at both 9 and 10 September 2026; repurchased shares remain outstanding until formal cancellation. • 30-day issuance lock-up: In line with HKEX rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 October 2026 following the latest repurchase.

The company confirmed that all repurchases were conducted in compliance with Hong Kong listing regulations and the terms of the shareholder mandate granted on 26 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1177513912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177513912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177513912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177513912","market":"us","top_or_hot":-1,"title":"PW Medtech discloses 700,000-share repurchase on 10 September; cumulative buybacks rise to 4.41 million shares","media":"Bulletin Express","content":"<p>PW Medtech Group Limited submitted a Next Day Disclosure Return to the Hong Kong Stock Exchange on 10 September 2026 detailing its latest share repurchase activity and current share capital position.</p>\n<p>Key points</p>\n<p>• Latest on-market buyback: On 10 September 2026 the company repurchased 700,000 ordinary shares on the Exchange at prices ranging from HKD 0.965 to HKD 0.98, for a total consideration of HKD 0.68 million.  \n• Ongoing cancellation process: Including this transaction, PW Medtech now holds 4.41 million shares pending cancellation—equivalent to 0.31% of the company’s issued share capital as at the 26 June 2026 mandate date.  \n• Repurchase mandate headroom: The board is authorised to buy back up to 144.29 million shares; purchases to date utilise approximately 3.06% of the approved limit.  \n• Share capital unchanged: Issued shares stood at 1.43 billion as at both 9 and 10 September 2026; repurchased shares remain outstanding until formal cancellation.  \n• 30-day issuance lock-up: In line with HKEX rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 October 2026 following the latest repurchase.</p>\n<p>The company confirmed that all repurchases were conducted in compliance with Hong Kong listing regulations and the terms of the shareholder mandate granted on 26 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PW Medtech discloses 700,000-share repurchase on 10 September; cumulative buybacks rise to 4.41 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPW Medtech discloses 700,000-share repurchase on 10 September; cumulative buybacks rise to 4.41 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-10 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PW Medtech Group Limited submitted a Next Day Disclosure Return to the Hong Kong Stock Exchange on 10 September 2026 detailing its latest share repurchase activity and current share capital position.</p>\n<p>Key points</p>\n<p>• Latest on-market buyback: On 10 September 2026 the company repurchased 700,000 ordinary shares on the Exchange at prices ranging from HKD 0.965 to HKD 0.98, for a total consideration of HKD 0.68 million.  \n• Ongoing cancellation process: Including this transaction, PW Medtech now holds 4.41 million shares pending cancellation—equivalent to 0.31% of the company’s issued share capital as at the 26 June 2026 mandate date.  \n• Repurchase mandate headroom: The board is authorised to buy back up to 144.29 million shares; purchases to date utilise approximately 3.06% of the approved limit.  \n• Share capital unchanged: Issued shares stood at 1.43 billion as at both 9 and 10 September 2026; repurchased shares remain outstanding until formal cancellation.  \n• 30-day issuance lock-up: In line with HKEX rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 October 2026 following the latest repurchase.</p>\n<p>The company confirmed that all repurchases were conducted in compliance with Hong Kong listing regulations and the terms of the shareholder mandate granted on 26 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01358","symbol_name":"普华和顺","start_time":0,"source_url":"","article_id":"1177513912","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177513912","pubTimestamp":1789040576,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"PW Medtech Group Limited submitted a Next Day Disclosure Return to the Hong Kong Stock Exchange on 10 September 2026 detailing its latest share repurchase activity and current share capital position....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01358":"普华和顺"},"translate_title":"PW Medtech 于 9 月 10 日披露回购 70 万股股票；累计回购量升至 441 万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01358":1},"content_text":"PW Medtech Group Limited submitted a Next Day Disclosure Return to the Hong Kong Stock Exchange on 10 September 2026 detailing its latest share repurchase activity and current share capital position.\nKey points\n• Latest on-market buyback: On 10 September 2026 the company repurchased 700,000 ordinary shares on the Exchange at prices ranging from HKD 0.965 to HKD 0.98, for a total consideration of HKD 0.68 million.  \n• Ongoing cancellation process: Including this transaction, PW Medtech now holds 4.41 million shares pending cancellation—equivalent to 0.31% of the company’s issued share capital as at the 26 June 2026 mandate date.  \n• Repurchase mandate headroom: The board is authorised to buy back up to 144.29 million shares; purchases to date utilise approximately 3.06% of the approved limit.  \n• Share capital unchanged: Issued shares stood at 1.43 billion as at both 9 and 10 September 2026; repurchased shares remain outstanding until formal cancellation.  \n• 30-day issuance lock-up: In line with HKEX rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 October 2026 following the latest repurchase.\nThe company confirmed that all repurchases were conducted in compliance with Hong Kong listing regulations and the terms of the shareholder mandate granted on 26 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}